Page last updated: 2024-12-06

5-fluoropyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID69605
MeSH IDM0093435

Synonyms (23)

Synonym
AC-453
BB 0260992
5-fluoropyrimidine ,
pyrimidine, 5-fluoro-
inchi=1/c4h3fn2/c5-4-1-6-3-7-2-4/h1-3
675-21-8
AKOS006346044
A9048
5-fluoro-pyrimidine
unii-l36x4td47c
l36x4td47c ,
FT-0601423
c4h3fn2
AM86123
W-203496
DTXSID80217851
mfcd06658278
Q42859845
F14737
pyrimidine, 5-fluoro- (6ci,8ci,9ci)
pyrimidine, 5--fluoro-
EN300-6966105
PD132042

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Toxicity consisted of 1 case of mild edema; no adverse events characteristic of fluoropyrimidines were recorded."( A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease.
Bajetta, E; Carnaghi, C; Somma, L; Stampino, CG,
)
0.13
" Our aim was to test the clinical validity of both novel and previously identified markers of adverse events in a broad clinical setting."( Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.
Barrett, A; Chu, GS; Epurescu, D; Jennings, BA; Keane, M; Loke, YK; Skinner, J; Turner, R; Willis, G, 2013
)
0.39
" There was no association between IVS14 + 1 G > A polymorphism and the occurrence of adverse reactions."( Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020
)
0.8
"FOLFOX and FOLFIRI were the most common regimens in CRC patients and their toxicity profile was different in some adverse reactions."( Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020
)
0.8

Pharmacokinetics

ExcerptReferenceRelevance
" The study also sought to identify pharmacodynamic (PD) determinants of both activity and toxicity."( High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Baker, SD; Burks, K; Donehower, RC; Grochow, LB; O'Reilly, S; Rowinsky, EK, 1998
)
0.3
" Plasma sampling with performed during course 1 to characterize the pharmacokinetic (PK) and PD behavior of TPT."( High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Baker, SD; Burks, K; Donehower, RC; Grochow, LB; O'Reilly, S; Rowinsky, EK, 1998
)
0.3
" The pharmacokinetic profiles of the tegafur, CDHP, and oxonic acid constituents were characterized."( Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004
)
0.32
" The pharmacokinetic data suggested potent inhibition of 5-FU clearance by CHDP, with resultant 5-FU exposure at least 10-fold higher than that reported from equitoxic doses of tegafur modulated by uracil in the oral fluoropyrimidine UFT."( Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004
)
0.32
" The pharmacokinetic data indicate substantial modulation of 5-FU clearance by CDHP."( Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004
)
0.32
" Unfortunately, such preclinical and clinical pharmacokinetic studies are rare."( Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.
Bocci, G; Kerbel, RS, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the efficacy and safety of trastuzumab combined with chemotherapy in the treatment for HER-2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma."( [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J, 2014
)
0.4
"Fluoropyrimidine combined with oxaliplatin-based chemotherapy have become the first-line treatment for advanced colorectal cancer (CRC)."( Efficacy of Chinese herbal injections combined with fluoropyrimidine and oxaliplatin-based chemotherapy for advanced colorectal cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Dong, J; Gui, Y; Hou, W; Hu, S; Li, Y; Li, Z; Tian, P; Wang, S; Wang, X; Zhang, Y; Zhou, T, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
"In sequential phase II studies assessing two dosing schedules, patients with metastatic colorectal cancers refractory to bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens received everolimus 70 mg/wk (n = 99) or 10 mg/d (n = 100)."( Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Arrowsmith, ER; Bajetta, E; Del Prete, SA; Fuchs, CS; Hwang, J; Jin, J; Malek, K; Ng, K; Ryan, DP; Sedova, M; Sharma, S; Tabernero, J, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (11.76)18.7374
1990's16 (18.82)18.2507
2000's27 (31.76)29.6817
2010's28 (32.94)24.3611
2020's4 (4.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.83 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index32.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (12.36%)5.53%
Reviews20 (22.47%)6.00%
Case Studies1 (1.12%)4.05%
Observational0 (0.00%)0.25%
Other57 (64.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]